Cero Therapeutics Files 8-K on Equity Sales
Ticker: CEROW · Form: 8-K · Filed: Jun 6, 2025 · CIK: 1870404
Sentiment: neutral
Topics: equity-sale, biotech, filing
Related Tickers: CERO
TL;DR
CERO filed an 8-K for unregistered equity sales - watch for dilution.
AI Summary
Cero Therapeutics Holdings, Inc. filed an 8-K on June 6, 2025, reporting unregistered sales of equity securities and other events. The filing details the company's operations as a biotechnology firm focused on biological products, with its principal executive offices located in South San Francisco, California.
Why It Matters
This filing indicates potential dilution for existing shareholders due to unregistered equity sales, which could impact the stock price.
Risk Assessment
Risk Level: medium — Unregistered sales of equity securities can lead to dilution and signal potential financial distress or a need for capital.
Key Players & Entities
- CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
- June 5, 2025 (date) — Date of earliest event reported
- June 6, 2025 (date) — Date of Report
- South San Francisco, California (location) — Business Address
- PHOENIX BIOTECH ACQUISITION CORP. (company) — Former Company Name
FAQ
What type of securities were sold in the unregistered offering?
The filing explicitly states 'Unregistered Sales of Equity Securities' but does not specify the exact type of equity in the provided text.
When was the earliest event reported in this 8-K?
The earliest event reported was on June 5, 2025.
What is Cero Therapeutics Holdings, Inc.'s primary business?
The company is involved in 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' as indicated by its SIC code.
What was Cero Therapeutics Holdings, Inc. formerly known as?
The company was formerly known as PHOENIX BIOTECH ACQUISITION CORP.
Where are Cero Therapeutics Holdings, Inc.'s principal executive offices located?
The principal executive offices are located at 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA 94080.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 6, 2025 regarding CERO THERAPEUTICS HOLDINGS, INC. (CEROW).